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COST-EFFECTIVENESS OF BLOOD PRESSURE LOWERING WITH A FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE IN TYPE 2 DIABETES MELLITUS: A TRIAL-BASED ANALYSIS USING THE ADVANCE STUDY
Clarke PM 1 , Glasziou P 2 , Alexander J 3 , Chalmers J 4 , Patel A 5 1 University of Sydney, Sydney, NSW, Australia; 2 University of Oxford, Oxford, Oxfordshire, UK; 3 University of Queensland, Brisbane, Australia; 4 George Institute, Sydney, Australia; 5 George Institute, Sydney, Australia OBJECTIVES: To determine the cost-effectiveness of routine administration, irrespective of blood pressure, of a fi xed-dose combination of perindopril and indapamide to patients with Type 2 diabetes. METHODS: Prospective cost-effectiveness analysis within a 20 country randomized trial of 11,140 patients with Type 2 diabetes randomized to perindopril plus indapamide or placebo. We calculated cost per death averted at 4.3 years average follow-up and estimated cost per life-year gained by extrapolation. RESULTS: The ADVANCE trial showed a 14% relative risk reduction in all cause mortality (P < 0.03) and an 18% relative risk reduction (0.8% absolute reduction) in cardiovascular mortality (P < 0.03). Hospital admissions for coronary heart disease and coronary revascularization were reduced by 5%. Per patient perindopril-indapamide cost AUS$1368, but reduced total hospitalization costs by AUS$410 and other medication costs (mainly other blood pressure lowering drugs) by AUS$332. Quality of life, measured by the EQ-5D, was 0.80 (on a 0-1 scale); with no difference between groups. Absolute reduction in all-cause mortality was 1.1%, giving a cost per life saved of AUS$49,200, and life-time extrapolation estimated a cost per life-year saved of AUS$8,470 (discounted at 3%). CONCLUSIONS: The combination of perindopril and indapamide in patients with type 2 diabetes reduces all-cause mortality and appears cost-effective.
HT4 HEALTH TECHNOLOGY ASSESSMENT DATABASE IN THAILAND
Kapol N 1 , Lochid-amnuay S 2 , Chalongsuk R 2 , Maitreemit P 2 , Sribundit N 2 , Amrumpai Y 2 1 Silpakorn University, Nakorn Pathom, Thailand; 2 Silpakorn University, A. Muang, Nakhon Pathom, Thailand BACKGROUND: Health technology assessment is a pivotal tool to assist policymakers to decide whether a health technology is effi cient. However, the accessibility of health technology assessment information in Thailand is problematic. Attempts to develop Thai health technology assessment database has been raised. The database aims to increase accessibility and utility to policymakers, researchers and practitioners. From January 2008, Thai health technology assessment database has been available online at http://www.db.hitap.net. OBJECTIVES: The objectives of this study are to determine current contents of the database and evaluate the usefulness of the database. METHODS: A review of the Thai health technology assessment database was conducted to determine the main characteristics of studies, the number of included studies, the number of database members, and number of visitors. Moreover, the use of the database was evaluated by an electronic mail survey to 260 website members. RESULTS: By the end of 2009, the database consisted of 732 articles including three types of studies, 155 full economic evaluation studies, 471 randomized control trials studies and 106 quality of life studies. The number of database members is 711. The number of visitors increases from 1123 to 1717 hits per month in 2008 and 2009, respectively. For the survey results, of 260 members, 41 respondents (15.77%) replied to the electronic mail survey. Most of them used the database for studying and/ or conducting a research. The usefulness of the database was found most in 65.86% of respondents. CONCLUSIONS: Thai health technology assessment database provided useful information to users. However, some types of studies should be included to support potential users' needs. Moreover, the registration system for the members should be further improved to follow up and effectively disseminate information to users.
PODIUM SESSION I: INFECTIOUS DISEASE STUDIES
IN1 ECONOMIC AND CLINICAL BURDEN OF PNEUMOCOCCAL DISEASES AND ACUTE OTITIS MEDIA IN TAIWAN: A NATIONWIDE POPULATION-BASED DATABASE ANALYSIS
Chang CJ 1 , Wang PC 2 , Huang YC 3 , Wu BS 4 1 Chang Gung University, Taoyuan, Taiwan; 2 Cathay General Hospital, Taipei, Taiwan; 3 Chang Gung Memorial Hospital, Taoyuan, Taiwan; 4 National Yang-Ming University, Taipei, Taiwan OBJECTIVES: Streptococcus pneumonia can cause invasive diseases such as meningitis and bacteremia, and noninvasive diseases such as pneumonia and acute otitis media (AOM), leading to high morbidity and mortality in infants and the elderly. Limited data are available for the burden of these diseases in Taiwan. This study investigates economic and clinical burden of pneumococcal diseases and AOM in Taiwan. METHODS: A retrospective population-based National Health Insurance Reimbursement Database (NHIRD) study was performed to estimate the incidence and direct medical costs of pneumococcal meningitis/bacteremia/pneumonia and AOM from 2002 to 2007 from healthcare provider perspective, including only NHIcovered costs. RESULTS: The incidence of pneumococcal meningitis is 0.1 per 100,000 and highest at age <1 (2.4 per 100,000) and decreases with age. The incidence of pneumococcal bacteremia is 0.9 per 100,000 with peak at 7.1 per 100,000 at age 75 and above, followed by 3.7 at age 2 and 3. The incidence of pneumococcal pneumonia is 165.1 per 100,000 with peak at 1060.9 per 100,000 at age 75 and above, followed by 1230.7 per 100,000 at age 1, followed by 1076.9 per 100,000 at age 2. The AOM incidence is 2,729.1 per 100,000 with peak at 23,078.8 per 100,000 at age 1, and high in children group (9,641 per 100,000 at age 12 and below). Annually, 120 deaths are estimated to cause by pneumococcal diseases. The total annual medical cost is US$110,886,546. The annual cost for pneumococcal meningitis is US$193,021, mainly for inpatients (US$189, 794) . The annual cost for pneumococcal bacteremia is US$744,573, mainly for inpatients (US$732, 282) . For pneumococcal pneumonia, the total annual cost is US$74,029,821 mainly for inpatients (US$66, 353, 242) . For AOM, the annual cost is US$35,919,131, US$18,059,540 for inpatients and US$17,859,590 for out-patients. CONCLUSIONS: Our study shows huge burden of pneumococcal diseases and AOM in Taiwan. Prevention of these diseases will help reduce clinical and economic burden.
IN2
COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR TUBERCULOSIS CONTROL PROGRAMS IN THAILAND
Hunchangsith P, Barendregt JJ, Vos T, Bertram M The University of Queensland, Brisbane, Queensland, Australia OBJECTIVES: To evaluate the cost-effectiveness of different strategies to control tuberculosis (TB) in Thailand. METHODS: Strategies included directly observed treatment (DOT) by a health worker, community member, or family member, and a mobile phone "contact-reminder" system, compared to self-administered treatment (SAT). Cost-effectiveness analysis was undertaken using a decision tree model, which had three stages of treatment; initial treatment, re-treatment, and multi-drug resistant TB (MDR-TB) treatment. Costs (2005 international dollars: I$) were calculated based on treatment periods and treatment outcomes. Health outcomes were estimated over the lifetime of smear-positive pulmonary TB patients in disability-adjusted life-years (DALYs). Both costs and health outcomes were discounted at 3%. RESULTS: Costeffectiveness results did not clearly indicate a preference for any of the interventions analyzed. Although the median cost-effectiveness ratio for each DOT intervention was favorable, the uncertainty ranges surrounding the health benefi ts were wide, including a sizeable probability that SAT could lead to more health gain than DOT strategies. The health gain in DALY for family-member DOT was 9400 DALY (95% uncertainty interval −7200 to 25,000), for community-member DOT was 13,000 (−21,000 to 37,000) and health-worker DOT was 7900 (−50,000 to 43,000). There were costsavings (from less re-treatment or MDR-TB treatment) associated with family-member DOT (-I$9 million (-I$12 million to -I$5 million)) as the trial treatment failure rate was signifi cantly lower than for SAT. The mobile phone reminder system was not cost-effective, as the mortality rate in the small trial of this intervention was much
